Last reviewed · How we verify
Placebo for add-back therapy — Competitive Intelligence Brief
phase 3
Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for add-back therapy (Placebo for add-back therapy) — Bio Genuine (Shanghai) Biotech Co., Ltd.. This drug serves as a placebo for add-back therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for add-back therapy TARGET | Placebo for add-back therapy | Bio Genuine (Shanghai) Biotech Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for add-back therapy CI watch — RSS
- Placebo for add-back therapy CI watch — Atom
- Placebo for add-back therapy CI watch — JSON
- Placebo for add-back therapy alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for add-back therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-add-back-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab